Residential sales in Hong Kong continue to improve, and mainland China sales are on track, embattled company says.

New shades of capitalism are emerging in China's tuckered out stock market as companies, at Beijing's behest, buy back their shares and pay record dividends to investors lying in wait for a so-far evasive rebound.

Asian equities ended the week on a high note, as Mainland China and Hong Kong outperformed and the Philippines underperformed.

The Hong Kong stock market has finished higher in six straight sessions, rallying more than 1,230 points or 6 percent in that span.

China announced plans on Thursday to channel hundreds of billions of yuan of investment from state-owned insurers into shares as part of the government's latest efforts to support a struggling stock market.

US President Donald Trump had threatened 60% tariffs on Chinese goods on his campaign trail.

On Monday, Hong Kong-listed growth stocks had a strong day, as the Hang Seng Index gained +1.75% and the Hang Seng Tech Index gained +2.59% following U.S. President Donald Trump and China President Xi Jinping’s Friday phone call that took place after Asia markets closed and before the U.S. markets opened.

The Company makes available through the Investor Relations section of its internet website at http://ir.yumchina.com its filings with the HKEX as soon as reasonably practicable after electronically filing such materials with the HKEX. These filings may also be obtained by visiting the HKEX's website at http://www.hkex.com.hk.

The Chinese government is trying to encourage people to spend more by ensuring that share prices will rise, ordering pensions and mutual funds to invest more in domestic stock markets

Global shares rose on Friday buoyed by the prospect of lower U.S. interest rates and a U.S.-China trade deal following comments from President Donald Trump, while the yen was choppy after the Bank of Japan delivered a widely expected rate hike.

In Tokyo, the Nikkei 225 index was up 1.5% at 39,604.71 after Trump announced a joint venture that aims to invest up to $500 billion in infrastructure related to artificial intelligence. Softbank Group Corp.'s Japan-listed shares surged 8.9% on Wednesday.

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to develop and commercialize ICP-B02 as a cancer drug outside of China. Prolium also has the right to develop ICP-B02 in non-cancer indications globally, according to a filling with the Hong Kong Stock Exchange (PDF).